Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

INTERCEPT-GPC3: Interleukin-15 and -21 Armored Glypican-3 Specific Chimeric Antigen Receptor Expressing Autologous T-cells in Adults With GPC3-positive Solid Tumors

NCT07224568 is registered in ClinicalTrials.gov with Seattle Children's Hospital as lead sponsor.

NCT NCT07224568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07224568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
INTERCEPT-GPC3: Interleukin-15 and -21 Armored Glypican-3 Specific Chimeric Antigen Receptor Expressing Autologous T-cells in Adults With GPC3-positive Solid Tumors
Lead sponsor
Seattle Children's Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
April 1, 2026
Completion date
August 31, 2045
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma, liposarcoma, liver cell carcinoma, rhabdomyosarcoma, solid tumor (excluding cns), yolk sac tumor